Registro:

Referencias:

• Coley, W.B., The treatment of inoperable sarcoma by bacterial toxins (The mixed toxins of the Streptococcus ery-sipelas and the Bacillus prodigiosus) (1910) Proc R Soc Med, 3, pp. 1-48
• Bayry, J., Autoimmunity: CTLA-4: A key protein in autoimmunity (2009) Nat Rev Rheumatol, 5, pp. 244-245
• Wherry, E.J., Kurachi, M., Molecular and cellular insights into T cell exhaustion (2015) Nat Rev Immunol, 15, pp. 486-499
• Sakuishi, K., Apetoh, L., Sullivan, J.M., Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity (2010) J Exp Med, 207, pp. 2187-2194
• Goldberg, M.V., Drake, C.G., LAG-3 in cancer immunotherapy (2011) Curr Top Microbiol Immunol, 344, pp. 269-278
• Manieri, N.A., Chiang, E.Y., Grogan, J.L., TIGIT: A key inhibitor of the cancer immunity c (2017) Trends Immunol, 38, pp. 20-28
• Antonioli, L., Pacher, P., Vizi, E.S., CD39 and CD73 in immunity and inflammation (2013) Trends Mol Med, 19, pp. 355-367
• Lines, J.L., Pantazi, E., Mak, J., VISTA is an immune checkpoint molecule for human T cells (2014) Cancer Res, 74, pp. 1924-1932
• Moon, Y.W., Hajjar, J., Hwu, P., Targeting the indole-amine 2,3-dioxygenase pathway in cancer (2015) J Immunother Cancer, 3, p. 51
• Long, G.V., Dummer, R., Hamid, O., Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study (2018) Australia: ASCO
• Rabinovich, G.A., Croci, D.O., Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer (2012) Immunity, 36, pp. 322-335
• Rubinstein, N., Alvarez, M., Zwirner, N.W., Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: A potential mechanism of tumor-immune privilege (2004) Cancer Cell, 5, pp. 241-251
• Juszczynski, P., Ouyang, J., Monti, S., The AP1-depen-dent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma (2007) Proc Nat Acad Sci USA, 104, pp. 13134-13139
• Soldati, R., Berger, E., Zenclussen, A.C., Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments (2012) Int J Cancer, 131, pp. 1131-1141
• Dalotto-Moreno, T., Croci, D.O., Cerliani, J.P., Targeting galectin-1 overcomes breast cancer-associated immu-nosuppression and prevents metastatic disease (2013) Cancer Res, 73, pp. 1107-1117
• Banh, A., Zhang, J., Cao, H., Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis (2011) Cancer Res, 71, pp. 4423-4431
• Martínez-Bosch, N., Fernández-Barrena, M.G., Moreno, M., Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation (2014) Cancer Res, 74, pp. 3512-3524
• Coley, W.B., The treatment of inoperable sarcoma by bacterial toxins (The mixed toxins of the Streptococcus ery-sipelas and the Bacillus prodigiosus) (1910) Proc R Soc Med, 3, pp. 1-48
• Rabinovich, G.A., Conejo-Garcia, J.R., Shaping the immune landscape in cancer by galectin-driven regulatory pathways (2016) J Mol Biol, 428, pp. 3266-3281
• Toscano, M.A., Bianco, G.A., Ilarregui, J.M., Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death (2007) Nat Immunol, 8, pp. 825-834
• Mendez-Huergo, S.P., Blidner, A.G., Rabinovich, G.A., Galectins: Emerging regulatory checkpoints linking tumor immunity and angiogenesis (2017) Curr Opin Immunol, 45, pp. 8-15
• Ilarregui, J.M., Croci, D.O., Bianco, G.A., Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10 (2009) Nat Immunol, 10, pp. 981-991
• Croci, D.O., Salatino, M., Rubinstein, N., Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi’s sarcoma (2012) J Exp Med, 209, pp. 1985-2000
• Croci, D.O., Cerliani, J.P., Dalotto-Moreno, T., Glycosyl-ation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors (2014) Cell, 156, pp. 744-758
• Nishino, M., Ramaiya, N.H., Hatabu, H., Monitoring immune-checkpoint blockade: Response evaluation and bio-marker development (2017) Nat Rev Clin Oncol, 14, pp. 655-668
• Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy (2015) Science, 348, pp. 69-74
• Peggs, K.S., Quezada, S.A., Allison, J.P., Cancer immunotherapy: Co-stimulatory agonists and co-inhibitory antagonists (2009) Clin Exp Immunol, 157, pp. 9-19
• Imai, C., Mihara, K., Andreansky, M., Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia (2004) Leukemia, 18, pp. 676-684
• Sanmamed, M.F., Pastor, F., Rodriguez, A., Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS (2015) Sem Oncol, 42, pp. 640-655
• Linch, S.N., McNamara, M.J., Redmond, W.L., OX40 Agonists and combination immunotherapy: Putting the pedal to the metal (2015) Front Oncol, 5, p. 34
• Fan, X., Quezada, S.A., Sepulveda, M.A., Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy (2014) J Exp Med, 211, pp. 715-725
• Amatore, F., Gorvel, L., Olive, D., Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy (2018) Expert Opin Ther Targets, 22, pp. 343-351
• Knee, D.A., Hewes, B., Brogdon, J.L., Rationale for anti-GITR cancer immunotherapy (2016) Eur J Cancer, 67, pp. 1-10
• Weigelin, B., Bolaños, E., Teijeira, A., Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb (2015) Proc Natl Acad Sci USA, 112, pp. 7551-7556
• Mitchinson, N.A., Dube, O.L., Studies on the immunological response to foreign tumor transplants in the mouse (1955) J Exp Med, 102, pp. 157-177
• Morgan, D.A., Ruscetti, F.W., Gallo, R., Selective in vitro growth of T lymphocytes from normal human bone marrows (1976) Science, 193, pp. 1007-1008
• Rosenberg, S.A., Spiess, P., Lafreniere, R., A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes (1986) Science, 233, pp. 1318-1321
• Rosenberg, S.A., Packard, B.S., Aebersold, P.M., Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report (1988) N Engl J Med, 319, pp. 1676-1680
• Dudley, M.E., Wunderlich, J.R., Robbins, P.F., Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes (2002) Science, 298, pp. 850-854
• Rosenberg, S.A., Yang, J.C., Sherry, R.M., Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy (2011) Clin Cancer Res, 17, pp. 4550-4557
• Besser, M.J., Shapira-Frommer, R., Itzhaki, O., Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: Intent-to-treat analysis and efficacy after failure to prior immunotherapies (2013) Clin Cancer Res, 19, pp. 4792-4800
• Klaver, Y., Kunert, A., Sleijfer, S., Adoptive T-cell therapy: A need for standard immune monitoring (2015) Immunotherapy, 7, pp. 513-533
• Robbins, P.F., Morgan, R.A., Feldman, S.A., Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 (2011) J Clin Oncol, 29, pp. 917-924
• Coley, W.B., The treatment of inoperable sarcoma by bacterial toxins (The mixed toxins of the Streptococcus ery-sipelas and the Bacillus prodigiosus) (1910) Proc R Soc Med, 3, pp. 1-48
• Kawakami, Y., Eliyahu, S., Delgado, C.H., Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection (1994) Proc Natl Acad Sci USA, 91, pp. 6458-6462
• Kawakami, Y., Eliyahu, S., Delgado, C.H., Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor (1994) Proc Natl Acad Sci USA, 91, pp. 3515-3519
• Imai, C., Mihara, K., Andreansky, M., Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia (2004) Leukemia, 18, pp. 676-684
• Song, D.G., Ye, Q., Carpenito, C., In vivo persistence, tumor localization, and antitumor activity of CAR-engi-neered T cells is enhanced by costimulatory signaling through CD137 (4-1BB) (2011) Cancer Res, 71, pp. 4617-4627
• Rosenberg, S.A., Restifo, N.P., Adoptive cell transfer as personalized immunotherapy for human cancer (2015) Science, 348, pp. 62-68
• Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., B-cell depletion and remissions of malignancy along with cy-tokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells (2012) Blood, 119, pp. 2709-2720
• Grupp, S.A., Kalos, M., Barrett, D., Chimeric antigen receptor-modified T cells for acute lymphoid leukemia (2013) N Engl J Med, 368, pp. 1509-1518
• Kakarla, S., Gottschalk, S., CAR T cells for solid tumors: Armed and ready to go? (2014) Cancer J, (2), pp. 151-155
• Kalaitsidou, M., Kueberuwa, G., Schütt, A., CAR T-cell therapy: Toxicity and the relevance of preclinical models (2015) Immunotherapy, 7, pp. 487-497
• Kalos, M., June, C.H., Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology (2013) Immunity, 39, pp. 49-60
• Bonifant, C.L., Jackson, H.J., Brentjens, R.J., Toxicity and management in CAR T-cell therapy (2016) Mol Ther Oncolytics, 3, p. 16011
• Roybal, K.T., Rupp, L.J., Morsut, L., Precision tumor recognition by T cells with combinatorial antigen-sensing circuits (2016) Cell, 164, pp. 770-779
• Zhang, H., Chua, K.S., Guimond, M., Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells (2005) Nat Med, 11, pp. 1238-1243
• Ku, C.C., Murakami, M., Sakamoto, A., Control of homeostasis of CD8+ memory T cells by opposing cytokines (2000) Science, 288, pp. 675-678
• Berger, C., Berger, M., Hackman, R.C., Safety and immunologic effects of IL-15 administration in nonhuman primates (2009) Blood, 114, pp. 2417-2426
• Wang, X., Popplewell, L.L., Wagner, J.R., Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL (2016) Blood, 127, pp. 2980-2990
• Liu, X., Ranganathan, R., Jiang, S., A chimeric switch-receptor targeting PD1 augments the efficacy of second generation CAR T-Cells in advanced solid tumors (2016) Cancer Res, 76, pp. 1578-1590
• Chmielewski, M., Kopecky, C., Hombach, A.A., IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression (2011) Cancer Res, 71, pp. 5697-5706
• Swart, M., Verbrugge, I., Beltman, J., Combination approaches with immune-checkpoint blockade in cancer therapy (2016) Front Oncol, 6, p. 223
• John, L.B., Devaud, C., Duong, C.P., Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells (2013) Clin Cancer Res, 19, pp. 5636-5646
• Sunblad, V., Morosi, L.G., Geffner, J.R., Galectin-1: A jack-of-all-trades in the resolution of acute and chronic inflammation (2017) J Immunol, 199, pp. 3721-3730
• Chen, D.S., Mellman, I., Oncology meets immunology: The cancer-immunity cycle (2013) Immunity, 39, pp. 1-10

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------